the educational message by invidual and group monthly meetings. 6-monthly follow-up in a year. We performed 24 hours ABPM using a SpaceLabs device at the beginning of the program and at the end of the period of intensive treatment (70 Ϯ 24 days after). The table shows the result of the data analysis:
Background: Anorexigens have been associated with cardiovascular side effects including heart rate (HR), blood pressure (BP) and valvular changes. We assessed the effect of sibutramine (sib), a monoamine reuptake inhibitor, on HR, BP, LV geometry and function and heart valves. Methods: non complicated obese patients (n ϭ 184, 30 Յ BMI Ͻ 40 kg/m2) were randomized double blind to 6 months o.d. sib 10 mg (n ϭ 64) or 20 mg (n ϭ 60) or placebo (n ϭ 60). 2D-Echos were obtained using an ATL Peak 800ϩ machine, LV mass index (LVMI) was calculated according to Devereux and Reichek and adjusted for height. Heart valves were examined in various axes. Echo data were obtained for 173 patients (10 mg ϭ 61, 20 mg ϭ 56 or placebo ϭ 56). Echo were performed at baseline (twice Ϫ poor quality and/or reproducibility echo were excluded) and at 6 months by a single operator. Results: Baseline patients' characteristics, comparable between the 3 treatment groups, were as follows: age ϭ 38.7 Ϯ 10.8 yrs, 85% female, BMI ϭ 33.8 Ϯ 2.8 kg/m 2 , SBP/DBP ϭ 121.4 Ϯ 11.7/75.3 Ϯ 8.6 mmHg, LVMI ϭ 60.8 Ϯ 15.9 g/m, LVEF ϭ 65.0 Ϯ 5.4%; grade 1 or 2 valve regurgitation was found in 11% (mitral), 8% (aortic), and 3% (tricuspid) of patients. At 6 months sib decreased BMI (ANOVA) (10 mg: Ϫ3.5 Ϯ 2.1 vs 20 mg: Ϫ4.4 Ϯ 2.5 vs placebo Ϫ1.7 Ϯ 1.6, p Ͻ 0.001) and slightly increased HR (ϩ5.7 vs ϩ5.8 vs ϩ0.1bpm, p ϭ 0.001). SBP and DBP and ECG variables, including QT and QTc, were unchanged. Statistically significant differences for LVMI reductions were seen in the sib groups from baseline (p Ͻ 0.01) but pairwise comparisons with placebo were not significant (Ϫ4.4, Ϫ4.3 vs Ϫ3.0). Valvular changes were not significant. Conclusion: Obese patients treated with sib 10 mg or 20 mg or placebo for 6 ••• falls in LVM associated with weight loss; these falls were significantly greater for the sib groups from baseline. Also, apart from a slight rise in HR, sib did not affect BP, ECG variables and heart valves.
E017 ARTERIAL HYALINOSIS IN KIDNEY VESSELS. A REAL INDEX FOR RENAL PROGNOSIS IN DIABETIC PATIENTS?
J.E. Toblli*, G. DeRosa, G. Cao, E. Maronna, and R. Ibarra.
Hospital Alemán-Hospital de Clinicas, Buenos Aires, Argentina
Diabetes mellitus (DM) exerts its greatest impact throughout the vascular system. Moreover, large vessel disease contributes significantly to premature morbidity and mortality in DM. On the other hand, the development of high blood pressure is an additional well-known risk factor in the DM scenario. The aim of this study was to evaluate the arterial hyalinosis (AH) in renal tissue in patients with DM and correlate this finding with glomerular sclerosis (GS), interstitial fibrosis (IF), renal function and blood pressure. Twenty-six renal biopsy (RB) specimens from patients with DM (NIDDM n ϭ 15 and IDDM n ϭ 11), 21 male and 5 female with a mean age of 49 years (range, 27 to 63 years). Evolution time of DM 12 Ϯ 7 years. RB tissue was processed for LM by standard techniques. Vessels lesions were graded according to Raij score used for glomerular sclerosis, with modifications (Kidney Int 1984; 26:137-143 
